Melanocyte stimulating hormone coupled to Sepharose effects an increase in tyrosinase (EC 1.14.18.1; monophenol monooxygenase) activity of cultivated mouse melanoma cells. Synchronized cells are found to respond to melanocyte stimulating hormone only in the G2 phase of the cell cycle, although their response to cyclic AMP is independent of position in the cell cycle. The binding of 125I-labeled melanocyte stimulating hormone occurs predominantly in G2. These observations are satisfied by a model in which the hormone can activate adenylate cyclase (EC 4.6.1.1) by binding to a melanocyte stimulating hormone receptor only in G2; the events distal to cyclic AMP production can occur throughout the cell cycle.
A mouse melanoma cell line has been described which responds dramatically to melanoyte stimulating hormone (MSH). This peptide hormone effects large increases in tyrosinase (EC 1.14.18.1; monophenol monooxygenase) activity, melanin content, and intracellular levels of cyclic AMP, as well as changes in growth characteristics and cellular morphology (1, 2) . Cyclic AMP or its analogue, dibutyryl cyclic AMP, can substitute for MSH to produce the same responses. These findings are consistent with previous observations in mammals that MSH acts through cyclic AMP (3) (4) (5) . Studies with synchronized cells reveal that the effects of MSH are localized to a specific phase of the cell cycle. Whenever MSH is added to synchronized cells, increases in tyrosinase activity and cyclic AMP levels are maximal in the G2 phase (6) .
In this paper we wish to report our findings that melanocytes from a mouse melanoma respond to dibutyryl cyclic AMP throughout the cell cycle, but that the binding of labeled MSH to the cells is discontinuous and takes place only in G2.
MATERIALS AND METHODS
Culture Conditions. Melanocytes of the Cloudman mouse melanoma line (NCTC 3960, CCl 53) were cultured in 30-ml Falcon tissue-culture flasks. Synchronized cells were obtained by arresting the cells in mitosis with colchicine and harvesting them at that time as described (6) . Each flask was inoculated with 2 X 105 cells.
Abbreviations: MSH, P-melanocyte stimulating hormone (AspGlu-Gly-Pro-Tyr-Lys-Met-Glu-His-Phe-Arg-Try-Gly-Ser-ProPro-Lys-Asp); cAMP, adenosine-3: 5'-cyclic monophosphate; dibutyryl cAMP, N6,02'-dibutyryl -adenosine 3': 5'-cyclic monophosphate; PBS, phosphate-buffered saline (0.01 M Na-phosphate-0.15 M NaCl, pH 7.4).
Preparation of ln2I-Labeled MSH. 125I-labeled MSH was synthesized by the chloramine-T method (8) with the following modifications: 2.5 jug (10-9 mol) of #-MSH was iodinated for 15 see at room temperature with 5 mCi of carrier-free 1251 (New England Nuclear Corp.) in a total volume of 0.06 ml. The labeled peptide was separated from the other components of the reaction mixture on a 1 X 55-cm Sephadex G-10 column equilibrated with phosphate-buffered saline, pH 7.4 (PBS). The short exposure to a large excess of 12'I insures that only tyrosine (the fifth residue) is substituted, and at the same time high specific radioactivity (about 2000 Ci/mmol) is obtained. The preparation retained its original biological activity, i.e., melanoma cells exposed to the purified ln2I-labeled MSH responded with increased tyrosinase activity and melanization. Retention of biological activity was expected since the major portion of the activity resides in the middle heptapeptide of MSH, which does not contain tyrosine (9 closed and incubated at 370 for 15 min. The unbound 126I-labeled MSH was removed by rinsing the cells three times with 30 ml of PBS at room temperature. The flasks were then drained for 2 hr and dried in a vacuum dessicator at room temperature overnight. The marked area of the flask where 125I-labeled MSH had been applied (1 inch2) was cut out with a red-hot razor blade, and the side to which the cells were attached was marked with -radioactive ink to permit later alignment of the cells with the autoradiographs. The plates were pressed against x-ray film with the cells facing the film for 1-3 days. After the exposure was completed the plates were crushed and the radioactivity was determined in a gamma-counter.
['H]Thymidine Incorporation. The S-phase was determined by measuring the incorporation of ['Hithymidine into DNA (11) .
RESULTS
Location and Number of MSH-Binding Receptors. MSH, linked to Sepharose beads by covalent bonds, stimulated both tyrosinase activity and melanization (Table 1 ). These findings showed that MSH reacted with receptors at the cell surface.
After the cells were labeled in the G2 phase in the culture flask with 12-I-labeled MSH, and the cellular components separated by sedimentation in a sucrose density gradient (12), a major part of the MSH-binding activity was found to be in the plasma membrane fraction. 12"I-labeled MSH (Fig. 1) . The low level of binding in G1 was not a consequence of washing the cells away; the cells remained attached to the plastic substrate (Fig. 2B) . At the beginning of mitosis (45-50 hr after release from colchicine), a decline in MSH binding was seen in several experiments. The precise end of the MSH-binding period could not be located at this time because the cells were no longer synchronized.
Binding of MSH to Synchronized and Nonsynchronized Cells. Synchronized cells were highly homogeneous in their binding characteristics. In G2, virtually all of the cells were labeled ( Fig. 2A) , but in G1 practically none were (Fig. 2B) . As expected from these results, nonsynchronized cells were heterogeneous in their binding, some of the cells being labeled and others not (Fig. 2C) .
Sensitivity of MSH Binding to Proteolytic Treatment. One explanation for the absence of the binding of MSH in G1 and S would be that the availability of the MSH receptor is related to the configuration of the cell, which changes through the cycle (13) . It is possible that such masking of the receptor might be selectively eliminated by mild proteolytic treatment. In mouse melanoma cells such treatment completely abolished MSH binding. At various stages in the cell cycle, cells were incubated for 5 min with 10-50 ug/ml of trypsin or chymotrypsin. Afterwards, the enzymes were removed and 125I-labeled MSH was added. There was no binding in GI, S, or G2. Since the receptors were sensitive to proteolysis, we could not determine whether "masked" receptors were present when the cells were not in G2.
Effects of Dibutyryl Cyclic AMP on Tyrosinase Activity in Synchronized Cells. It has previously been demonstrated that either cyclic AMP (1) or its analogue, dibutyryl cyclic AMP (1, 4), can substitute for MSH in eliciting increased tyrosinase activity and melanin content in mouse melanoma cells. It has also been shown that increased tyrosinase activity and cyclic AMP content in response to MSH are seen only in the G2 phase of the cell cycle (6) . It is now clear that the reason for the localization in G2 is that the cells can bind MSH only in this phase of the cycle. It remained to be seen whether the response to cyclic AMP was also restricted to the G2 phase. Results in Fig. 3 show that the response of synchronized cells Melanoma cells (2 X 106) were inoculated into 30-ml Falcon tissue-culture flasks in 5 ml of culture medium. Tyrosinase activity was measured (1) after 48 hr of treatment with either culture medium only, freeB-MSH, or f5-MSH linked to Sepharose beads.
Tyrosinase activity was expressed as cpm of 3H20 released into 0.5 ml of culture medium per 24 hr. The numbers represent averages of duplicate culture flasks within the same experiment. The variation between duplicates was less than 10%. This experiment was repeated three times with similar results each time. the difference between tyrosinlase activities at each point was less than 5%. Tyrosinase activity is expressed as 3H20 released into 0.5 ml of culture medium per 8 hr.
DISCUSSION
We have demonstrated that MSH acts at the cell membrane and that the binding of MSH to the membrane of cultured melanoma cells is discontinuous and occurs primarily in the G2 phase of the cell cycle. The simplest explanation for this observation is that specific cell-surface receptors for MSH are available only in G2. It is likely that phenotypic expression of melanoma cells is regulated by the oscillation of the availability of these receptors. The reasons for localizing reception of binding to G2 and thereby restricting phenotypic expression are obscure, because the cells are able to respond to cyclic AMP throughout the cycle.
When cells are exposed to MSH in G2, cyclic AMP levels rise within 10 min; however, there is a lag period of 8-10 hr before increased tyrosinase activity is seen (6) . Cells exposed to dibutyryl cyclic AMP at any time in the cell cycle exhibit the same 8 to 10-hr lag period (Fig. 3) . This period is of interest because events leading to increased tyrosinase activity must occur during this time. We do not know whether the increased tyrosmnase activity is due to synthesis of new tyrosinase molecules or activation of preexisting ones.
A major question that emerges from these experiments is whether the MSH receptors appear in G2 from de novo synthesis or whether they are somehow masked during other phases of the cycle. The experiments with proteolytic digestion are inconclusive because even though we failed to "unmask" a silent receptor in Gi and S, we also destroyed receptor activity in G2. The extreme sensitivity of the receptors to proteolytic treatment indicates that proteins play a role in receptor activity. Recently, we found that MSH-receptor activity increases as the plasma membranes are purified. This finding is consistent with the possibility that a blocking moiety is lost during purification of the receptors.
Evidence from many sources has implicated cyclic AMP as the intracellular mediator for the response of melanocytes to MSH (1-6, 15, 16 it is likely that the sole role for MSH is to promote increbsed cyclic AMP concentrations within the cells. The melanocytes then respond to the higher levels of cyclic AMP with increased tyrosinase activity and melanin content, and changes in growth characteristics and morphology.
